Early detection of lung cancers - Comparison of computed tomography, cytology and fuzzy-based tumor markers panels

Cancer Biomarkers

Volumn 6, Issue 3-4, 2009, Pages 149-162

  Schneider, Joachim ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

computed tomography; Fuzzy classifier; Lung cancer; sputum cytology; tumor markers

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; PROGASTRIN RELEASING PEPTIDE; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ADVANCED CANCER; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CIGARETTE SMOKING; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; EARLY CANCER; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; FUZZY LOGIC; FUZZY SYSTEM; HIGH RISK POPULATION; HUMAN; LUNG ADENOCARCINOMA; LUNG NODULE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MULTIDETECTOR COMPUTED TOMOGRAPHY; PREDICTION AND FORECASTING; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SPUTUM CYTODIAGNOSIS; CYTOLOGY; LUNG NEOPLASMS; PROCEDURES;

CYTOLOGICAL TECHNIQUES; EARLY DETECTION OF CANCER; FUZZY LOGIC; HUMANS; LUNG NEOPLASMS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 77958178386     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2009-0126     Document Type: Review

References (97)

1. M. Akira, High-resolution CT in the evaluation of occupational and environmental disease, Radiol Clin North Am 40 (2002), 43-58.
2. K. Aoyagi, Y. Miyake, K. Urakami, T. Kashiwakuma, A. Hasegawa, T. Kodama and Yamaguchi, Enzyme immunoassay of immunoreactive progastrin-releasing peptide (31-98) as tumor marker for small cell lung carcinoma: development and evaluation, Clin Chem 41 (1995), 537-543.
3. G. Bastarrika, M. J. Gardá-Velloso, M. D. Lozano, U. Montes, W. Torre, N. Spiteri, A. Campo, L. Seijo, A. B. Alcaide, J. Pueyo, D. Cano, I. Vivas, O. Cosin, P. Dominguez, P. Serra, J. A. Richter, L. Montuenga and J. J. Zulueta, Early lung cancer detection using spiral computer tomography and positron emission tomography, Am J Respir Crit Care Med 171 (2005), 1378-1383.
4. C. J. Bérgin, N. L. Müller, S. Vedal and Chang-Yeung, CT in silicosis: correlation with plain films and pulmonary function tests, Am J Radiol 146 (1996), 477-483.
5. S. F. Bocklisch, N. Bitterlich, Fuzzy pattern classificationmethodology and application, in: Fuzzy Systems in Computer Science, R. Kruse, J. Gebhard and R. Palm, eds, Vieweg, Wiesbaden, 1994.
6. A. Böcking and H. Motherby, Sputumzytologie und DNA- Bildschirmzytometrie des Bronchialkarzinoms. In: Methoden zur Früherkennung von Lungenkrebs. Falkensteiner Tage 1998, Schriftenreihe des Hauptverbandes der gewerblichen Berufsgenossenschaften, Sankt Augustin (1998), 35-52.
7. O. C. Burghuber, B. Worofka, G. Schernthaner, N. Vetter, M. Neumann, R. Dudczak and R. Kuzmits, Serum neuron-specific enolase is a useful tumor marker for small cell lung cancer, Cancer 65 (1990), 1386-1390.
8. S. Chong, K. S. Lee, M. J. Chung, T. S. Kim, H. Kim, O. Jung Kwon, Y.-H. Choi and C. H. Rhee, Lung cancer screening with low-dose helical CT in Korea: Experiences at the Samsung Medical Center, J Korean Med Sci 20 (2005), 402-408.
9. G. P. A. Cruz and G. Beliakov, Fuzzy gating and the problem of screening, Artif Intell Med 8 (1996), 377-385.
10. S. Diederich, D. Wormanns and W. Heindel, Bronchialkarzinom-Screening mit Niedrigdosis-CT, Radiologe 41 (2001), 256-260.
11. S. Diederich, M. Thomas, M. Semik, H. Lenzen, N. Roos, A. Weber, W. Heindel and D. Wormanns, Screening for early lung cancer with low-dose spiral computed tomography: results of annual follow-up examinations in asymptomatic smokers. Eur Radiol 14 (2004), 691-702
12. W. Ebert, H. Dienemann, A. Fateh-Moghadam, M. Scheulen, N. Konietzko, T. Schleich and E. Bombardieri, Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study, Eur J Clin Chem Clin Biochem 32 (1994), 189-199. (Pubitemid 24096845)
13. Y. G. Fan, P. Hu, Y. Jiang, R. S. Chang, S. X. Yao, W. Wang, J. He, P. Prorok and Y. L. Qiao, Association Between Sputum Atypia and Lung Cancer Risk in an Occupational Cohort in Yunnan, China, Chest (2009), 778-785.
14. B. J. Flehinger, M. Kimmel and M. R. Melamed, Survival from early lung cancer: implications for screening, Chest 101 (1992), 1013-1018.
15. R. S. Fraser, N. L. Müller, N. Colman and P. D. Paré, Inhalation of inorganic dust (pneumoconiosis), in: Diagnosis of Diseases of the Chest, (4th ed.), R. S. Fraser, N. L. Müller, N. Colman and P. D. Paré, eds, Philadelphia: WB Saunders Co., 1999, pp. 2386-2484.
16. M. H. Gail, L. Muenz, K. R. Mc Intire, B. Radovich, G. Braunstein, P. R. Brown, L. Deftos, A. Dnistrian, M. Dunsmore and R. Elashoff, Multiple markers for lung cancer diagnosis: validation of models for advanced lung cancer, J Nat Cancer Inst 176 (1986), 805-816.
17. M. H. Gail, L. Muenz, Mc Intire, B. Radovich, G. Braunstein, P. R. Brown, L. Deftos, A. Dnistrian, M. Dunsmore, R. Elashoff, N. Geller, V. L. W. Go, K. Hirji, M. R. Klauber, D. Pee, G. Petroni, M. Schwartz and A. R. Wolfsen, Multiple markers for lung cancer diagnosis: validation of models for localized lung cancer, J Nat Cancer Inst 80 (1988), 97-101.
18. L. Giovanella, L. Ceriani, M. Bandera, R. Rimoldi, B. Beghe and G. Roncari, Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 21-1) immunoradiometric assay in non small cell lung cancer evaluation, Q J Nucl Med 39 (1995), 285-289.
19. J. K. Gohagan, P. M. Marcus, R. M. Fagerstrom, P. F. Pinsky, B. S. Kramer, P. C. Prorok, S. Ascher, W. Bailey, B. Brewer, T. Church, D. Engelhard, M. Ford, M. Fouad, M. Freedman, E. Gelmann, D. Gierada, W. Hocking, S. Inampudi, B. Irons, C. C. Johnson, A. Jones, G. Kucera, P. Kvale, K. Lappe, W. Manor, A. Moore, H. Nath, S. Neff, M. Oken, M. Plunkett, H. Price, D. Reding, T. Riley, M. Schwartz, D. Spizarny, R. Yoffie and C. Zylak, Lung screening study research group, Lung Cancer 47 (2005), 9-15.
20. K. Goto, T. Kodama, F. Hojo, K. Kubota, R. Kakinuma, T. Matsumoto, H. Ohmatsu, I. Sekine, K. Nagai and Y Nishiwaki, Clinicopathologic characteristics of patients with non-small cell lung carcinoma with elevated serum pro-gastrin-releasing peptide level, Cancer 82 (1998), 1056-1061.
21. C. Gruber, R. Hatz, J. Reinmiedl, D. Nagel and P. Stieber, CEA, CYFRA 21-1, NSE, and ProGRP in the diagnosis of lung cancer: a multivariate approach, J Lab Med 32 (2008), 361-371.
22. D. Gur, Lung cancer screening: radiology's opportunity here and now, Radiology 238 (2006), 395-397.
23. C. I. Henschke, D. I. McCauley, D. F. Yankelvitz, D. P. Naidich, G. McGuiness, O. S. Miettinen, D. M. Libby, M. W. Pasmantier, J. Koizumi, N. K. Altorki and J. P. Smith, Early lung cancer action project: overall design and findings from baseline screening, Lancet 354 (1999), 99-105.
24. C. I. Henschke, D. F. Yankelewitz, D. M. Libby, M. W. Pasmantier, J. P. Smith, O. S. Miettinen, N. A. Altorki, D. Flieder, J. Koizani, M. Vazquez, D. I. McCantey, G. McGuinness and D. P. Naidich, Early Lung Cancer Action Projekt: initial findings on repeat screenings, Cancer 92 (2001), 153-159.
25. C. I. Henschke, D. F. Yankelewitz, D. M. Libby, M. W. Pasmantier, J. P. Smith and O. S. Miettinen, Survival of patients with stage 1 lung cancer detected on CT screening, N Engl J Med 355 (2006), 1763-1771.
26. C. I. Jack, J. D. Sheard, B. Lippitt, A. Fromholtz, C. C. Evans and C. R. Hind, Lung cancer in elderly patients: the role of induced sputum production to obtain a cytological diagnosis, Age Ageing 22 (1993), 227-229.
27. J. Jarvisalo, M. Hakama, P. Knekt, U. H. Stenman, A. Leino, L. Teppo, J. Maatela and A. Aromaa, Serum tumor markers CEA, CA 50, TATI, and NSEin lung cancer screening, Cancer 71 (1993), 1982-1988.
28. S. J. Jay, K. Wehr, D. P. Nicholson and A. L. Smith, Diagnostic sensitivity and specificity of pulmonary cytology: comparison of techniques used in conjunction with flexible fiber optic bronchoscopy, Acta Cytol 24 (1980), 304-312.
29. J. R. Jett, S. J. Swensen, D. E. Midthun, T. E. Hartman, G. L. Aughenbaugh, J. A. Sloan, A. M. Sykes, P. D. Scanlon, A. C. Halling and H. D. Tazelaar, Spiral computed tomography screening for lung cancer is ready for prime time, Am J Respir Crit Care Med 163 (2001), 812-815.
30. S. Kakari, E. Stringou, M. Toumbis, A. S. Ferderigos, E. Poulaki, K. Chondros, A. Dema, V. Kotsovoulou and N. Pavlidis, Five tumor markers in lung cancer: significance of total and "lipid"-bound sialic acid, Anticancer Res 11 (1991), 2107-2110.
31. T. Keller, N. Bitterlich, S. Hilfenhaus, H. Bigl, T. Löser and P. Leohardt, Tumour markers in the diagnosis of bronchial carcinoma: new options using fuzzy logic-based tumour marker profiles, J Cancer Res Clin Oncol 124 (1998), 565-574.
32. R. A. Kemp, D. M. Reinders and B. Turic, Detection of lung cancer by automated sputum cytometry, J Thorac Oncol 11 (2007).
33. H. Koga, K. Eguchi, T. Shinkai, T. Tamura, Y. Ohe, F. Oshita, N. Saijo, H. Kondo, K. Oki and H. Okura, Preliminary evaluation of the new tumor marker, CYFRA 21-1, in lung cancer patients, Jpn J Clin Oncol 24 (1994), 263-268.
34. H. Koga, K. Eguchi, T. Shinkai, T. Tamura, Y. Ohe, F. Oshita, N. Saijo, H. Kondo, K. Oki and H. Okura, Preliminary evaluation of the new tumour marker CYFRA 21-1 in lung cancer patients, Jpn J Clin Oncol 24 (1996), 263-268.
35. N. Kohno, Y. Hirasawa, K. Kondo, S. Fujioka, S. Fujino, M. Abe, A. Yokoyama, K. Hiwada, K. Watanabe and J. Nishimura, Comparative studies of CAM 123-6 and carcinoembryonic antigen for the serological detection of pulmonary adenocarcinoma, Cancer Detect Prev 21 (1997), 124-128.
36. T. Kraus and H. J. Raithel, Frühdiagnostik asbeststaubverursachter Erkrankungen, Schriftenreihe des Hauptverbandes der gewerblichen Berufsgenossenschaften, Sankt Augustin, (1998) 1-145.
37. B. Lam, S. Y. Lam, M. P. Wong, C. G. Ooi, D. Y. Fong, D. C. Lam, A. Y. Lai, C. M. Tam, C. B. Pang, M. S. Ip and W. K. Lam, Sputum cytology examination followed by autofluorescence bronchoscopy: a practical way of indentifying early stage lung cancer in central airway, Lung Cancer 64 (3) (2009), 289-294.
38. Y. C. Lee, P. C. Yang, S. H. Kuo and K. T. Luh, Tissue polypeptide antigen and carcinoembryonic antigen as tumor markers in lung cancer, J Formos Med Assoc 90 (1991), 631-636.
39. G. Loewen, N. Natarajan, D. Tan et al., Autofluorescence bronchoscopy for lung cancer surveillance based on risk assessment, Thorax 62 (2007), 335-340.
40. C. Lombardi, G. F. Tassi, G. Pizzicolo and F. Donato, Clinical significance of a multiple biomarker assay in patients with lung cancer. A study with logistic regression analysis, Chest 97 (1990), 639-644.
41. J. Lorenz, D. Gillmann-Blum, M. Jensen and R. Kreienberg, Neuron-specific enolase (NSE) and squamous cell carcinoma antigen (SCC) as serum markers in the diagnosis of bronchial carcinoma, Pneumologie 44 (1990), 1259-1263.
42. B. MacDougall and B. Weinerman, The value of sputum cytology, J Gen Intern Med 7 (1992), 11-13.
43. R. MacRedmond, G. McVey, M. Lee, D. Kemy, C. Foley, R. W. Costello and P. M. Logan, Screening for lung cancer using low dose CT scanning: results of 2 year follow up, Thorax 61 (2006), 54-56.
44. P. M. Marcus, E. J. Bergstrahl, M. H. Zweig, A. Harris, K. P. Offord and R. S. Fontana, Extended lung cancer incidence followup in the Mayo lung project and overdiagnosis, J Nat Cancer Inst 98 (2006), 748-756.
45. W. Marek, S. Krampe, N. J. Dickgreber, L. Nielsen, A. Muti, B. Khanavkar, K. M. Müller, Z. Atay, T. Topalidis and J. A. Nakhosteen, Automatisierte quantitative Image-Zytometrie bronchialer Spülungen bei Verdacht auf ein Bronchialkarzinom: Vergleich mit Zytologie, Histologie und Enddiagnose, Atemw-Lungenkrkh 24 (1998), 316-319.
46. W. Marek, G. Richartz, S. Philippou, L. Marek and N. Kotschy-Lang, Sputum screening for lung cancer in radon exposed uranium miners: A comparison of semi-automated sputum cytometry and conventional cytology, J Physiol Pharmacol 58 5 (2007), 349-361.
47. G. Mastrangelo, M. N. Ballarin, E. Bellini, R. Bizzotto, F. Zannol, F. Gioffre, M. Gobbi, G. Tessadri, L. Marchiori, G. Marangi, S. Bozzolan, J. H. Lange, F. Valentini and P. Spolaore, Feasibility of screening programme for lung cancer in former asbestos workers, Occup Med 58 (2008) 175-180.
48. T. C. Medici, R. Wehrli and A. Zullig, Early diagnosis of bronchial carcinoma using thoracic roentgen imaging and sputum cytology, Schweiz Med Wochenschr 117 (1987), 1448-1457.
49. Y. Miyake, T. Kodama and K. Yamaguchi, Pro-gastrinreleasing peptide (31-98) is a specific tumor marker in patients with small cell lung carcinoma, Cancer Res 54 (1994), 2136-2140.
50. R. Molina, X. Filella, J. M. Auge, R. Fuentes, I. Bover, J. Rifa, V. Moreno, E. Canals, N. Vinolas, A. Marquez, E. Barreiro, J. Borras and P. Viladiu, Tumor marker (CEA, CA 125, CYFRA 21-1, SCC and NSE) in Patients with non-small cell lung cancer as an aid in histological and prognosis. Comparison with the main clinical and pathological prognostic factors, Tumour Biol 24 (2003), 209-218.
51. D. Moro, D. Villemain, J. P. Vuillez, C. A. Delord and C. Brambilla, CEA, CYFRA 21-1 and SCC in non-small cell lung cancer, Lung Cancer 13 (1995), 169-176.
52. H. Motherby, S. Nicklaus, A. Berg, S. Ohler, B. Ross et al., Semiautomated monolayer preparation of bronchial secretions using AutoCyte PREP, Acta Cytol 43 (1999), 47-57.
53. J. L. Mulshine and D. C. Sullivan, Lung cancer screening, New England J Med 352 (2005), 2714-2720.
54. T. Nawa, T. Nakagawa, S. Kusano, Y. Kawasaki, Y. Sugawara and H. Nakata, Lung cancer screening using low-dose spiral CT, Chest 122 (2002), 15-20.
55. U. Pastorino, M. Bellomi, C. Bandoni, E. D. Fiori, P. Araldi, M. Picchio, G. Pelosi, P. Boyle and F. Fazio, Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results, Lancet 362 (2003), 593-597.
56. E. F. Patz, S. Rossi, D. H. Harpole, J. E. Herndon and P. C. Goodman, Correlation of tumor size and survival in patients with stage Ia non-small cell lung cancer, Chest 117 (2000), 1568-1571.
57. P. W. Payne, T. J. Sebo, A. Doudkine, D. Garner, C. MacAulay, S. Lam, J. C. LeRichie and B. Palcic, Sputum screening by quantitative microscopy: a reexamination of a portion of the National Cancer Institute Cooperative Early Lung Cancer Study, Mayo Clin Proc 72 (1997), 697-704.
58. M. Plebani, D. Basso, F. Navaglia, M. De Paoli, A. Tommasini and A. Cipriani, Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? Br J Cancer 72 (1995), 170-173.
59. Y. L. Qiao, M. S. Tockmann, L. Li, Y. S. Erozan, S. X. Yao, M. J. Barrett, W. H. Zhou, C. A. Giffen, X. C. Luo and P. R. Taylor, A case-cohort study of an early biomarker of lung cancer in a screening cohort of Yunnan tin miners in China, Cancer Epidemiol Biomarkers-Prev 6 (1997), 893-900.
60. L. F. Romanova, V. A. Khailenko, L. F. Kuznetsova, M. I. Davy-dov, D. V. Komov, V. L. Kulish, L. V. Platinski and E. V. Pod-dubskaia, (Determining the level of the tumor marker-neuron-specific enolase in patients with neoplastic and non-neoplastic diseases), Klin Med Mosk 69 (1991), 38-39.
61. U. M. Schmitt, P. Stieber, U. Hasholzner, H. Pahl, K. Hofmann and A. Fateh-Moghadam, Methodological and clinical evaluation of two automated enzymatic immunoassays as compared with a radioimmunoassay for neuron-specific enolase, Eur J Clin Chem Clin Biochem 34 (1996), 679-682.
62. J. Schneider, H. G. Velcovsky, H. Morr, N. Katz, K. Neu and E. Eigenbrodt, Comparison of the tumor markers Tumor M2-PK, CEA, CYFRA-21-1, NSE and SCC in the diagnosis of lung cancer, Anticancer Res 20 (2000), 5053-5058.
63. J. Schneider, Evaluation eines Panels ausgewählter Tumormarker und der Fuzzy-Logik-Analyse zur Früherkennung von Lungentumoren in arbeitsmedizinischen Hochrisikokollektiven. Habilitationsschrift zur Erlangung der Venia legendi des Fachbereichs Humanmedizin der Justus-Liebig- Universität Gießen (2002).
64. J. Schneider, N. Bitterlich, H. G. Velcovsky, H. Morr, N. Katz and E. Eigenbrodt, Fuzzy logic-based tumor-marker profiles improved sensitivity in the diagnosis of lung cancer, Int J Clin Oncol 7 (2002), 145-151.
65. J. Schneider, G. Peltri, N. Bitterlich, M. Philipp, H. G. Velcovsky, H. Morr, N. Katz and E. Eigenbrodt, Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients, Clin Exp Med 2 (2003), 185-191. (Pubitemid 36313185)
66. J. Schneider, G. Peltri, N. Bitterlich, K. Neu, H. G. Velcovsky, H. Morr, N. Katz and E. Eigenbrodt, Fuzzy logic based tumor marker-profiles, including a new marker Tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients, Anticancer Res 23 (2003), 899-906. (Pubitemid 36750892)
67. J. Schneider, M. Philipp, H. G. Velcovsky, H. Morr and N. Katz, Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung dieseases, Anticancer Res 23 (2003), 885-894.
68. J. Schneider, N. Bitterlich and G. Schulze, Improved sensitivity in the diagnosis of gastro-intestinal tumors by Fuzzy logicbased tumor marker profiles including the Tumor M2-PK, Anticancer Res 25 (2005), 1507-1516.
69. J. Schneider, Tumor markers in detection of lung cancer, Advances Clin Chem 42 (2006), 1-41.
70. J. Schneider, N. Bitterlich, N. Kotschy-Lang, W. Raab and H.-J. Woitowitz, A fuzzy classifier using a marker panel for the detection of lung cancer in asbestosis patients, Anticancer Res 27 (2007), 1869-1878.
71. M. D. Seemann, T. Beinert, H. Furst and U. Fink, An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions, Lung Cancer 26 (1999), 149-155.
72. N. Shijubo, K. Yamaguchi, M. Hirasawa, Y. Shibuya, M. Inuzuka, T. Kodama and S. Abe, Progastrin-releasing peptide (31-98) in idiopathic pulmonary fibrosis and sarcoidosis, Am J Respir Crit Care Med 154 (1996), 1694-1699.
73. Silicosis and silicate disease committee, Diseases associated with exposure to silica and non-fibrous silicate minerals, Arch Pathol Lab Med 112 (1988), 673-720.
74. A. Sing, N. Freudenberg, C. Kortsik, H. Wertzel, B. Klosa and J. Hasse, Comparison of the sensitivity of sputum and brush cytology in the diagnosis of lung carcinomas, Acta Cytol 41 (1997), 399-408.
75. T. Sobue, T. Suzuki, M. Matsuda, T. Horai, A. Kajita, K. Kuriyama, M. Fukuoka, Y. Kusunoki, M. Kikui and S. Ryu, Sensitivity and specificity of lung cancer screening in Osaka, Japan, Jpn J Cancer Res 82 (1991), 1069-1076.
76. T. Sobue, N. Moriyama, M. Kaneko, M. Kusumoto, T. Kobayashi, R. Tsuchiya, R. Kakinuma, H. Ohmatsu, K. Nagai, H. Nishiyama, E. Matsiu and K. Eguchi, Screening for lung cancer with low-dose helical computed tomography: Antilung cancer association project, J Clin Oncol 4 (2002), 911-920.
77. S. Sone, S. Takashima, F. Li, Z. Yang, T. Honda, Y. Maruyama, M. Hasegawa, T. Yamada, K. Kubo, K. Hanamura and K. Asakura, Mass screening for lung cancer with mobile spiral computed tomography scanner, Lancet 351 (1998), 1242-1245.
78. S. Sone, F. Li, Z. G. Yang, T. Honda, Y. Maruyama, S. Takashima, M. Hasegawa, S. Kawakami, K. Kuba, M. Hariuda and T. Yamanda, Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner, Br J Cancer 84 (2001), 25-32.
79. P. Stieber, H. Dienemann, A. Schalhorn, U. M. Schmitt, J. Reinmiedl, K. Hofmann and K. Yamaguchi, Pro-gastrinreleasing peptide (ProGRP)-A useful marker in small cell lung carcinomas, Anticancer Res 19 (1999), 2673-2678.
80. M. Sumitani, N. Takifuji, S. Nanjyo, Y. Imahashi, H. Kiyota, K. Takeda R. Yamamoto and H. Tada, Clinical relevance of sputum cytology and chest X-ray in patients with suspectedt lung tumors, Intern Med 47 (13) (2008), 1199-1205.
81. N. Sunaga, S. Tsuchiya, K. Minato, S. Watanabe, N. Fueki, H. Hoshino, T. Makimoto, S. Ishihara, R. Saito and M. Mori, Serum pro-gastrin-releasing peptide is a useful marker for treatment monitoring and survival in small-cell lung cancer, Oncology 57 (1999), 143-148.
82. S. J. Swensen, J. R. Jett, T. E. Hartmann, D. E. Midthun, J. A. Sloan, A.-M. Sykes, G. L. Aughenbaugh and M. A. Clemens, Lung cancer screening with CT: Mayo Clinic experience, Radiology 226 (2003), 756-761.
83. S. J. Swensen, J. R. Jett, T. E. Hartmann, D. E. Midthan, S. J. Mandieker, S. L. Hillmann, A. M. Sykes, G. L. Augenbaugh, A. O. Bangam and K. L. Allen, CT screening for lung cancer: five-year prospective experience, Radiology 235 (2005), 259-265.
84. M. Takada, Y. Kusunoki, N. Masuda, K. Matui, T. Yana, S. Ushijima, K. Iida, K. Tamura, T. Komiya, I. Kawase, N. Kikui, H. Morino and M. Fukuoka, Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase, Br J Cancer 73 (1996), 1227-1232.
85. The International Early Lung Cancer Action Program Investigators, Survival of patients with stage I lung cancer detected on CT screening, New England J Med 355 (2006), 1763-1771.
86. M. Tiitola, L. Kivisaari, M. S. Huuskonen, K. Mattson, H. Koskinen, H. Lehtola, A. Zitting and T. Vehmas, Computed tomography screening for lung cancer in asbestos-exposed workers, Lung Cancer 35 (2002), 17-22.
87. M. S. Tockman, Survival and mortality from lung cancer in a screened population: the John Hopkins Study, Chest 89 (1986), 324-325.
88. M. S. Tockmann, P. K. Gupta, J. D. Myers, J. K. Frost, S. B. Baylin, E. B. Gold, A. M. Chase, P. H. Wilkinson and J. L. Mulshine, Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: a new approach to early lung cancer detection, J Clin Oncol 6 (1988), 1685-1693.
89. Y. Toyoda, T. Nakayama, Y. Kusunold, H. Iso and T. Suzuki, Sensitivity and specificity of lung cancer screening using chest low-dose computes tomography, Brit J Cancer 98 (2008), 1602-1607.
90. T. Vehmas, L. Kivisaari, A. Zitting, K. Mattson, H. Nordman and M. Huuskonen, Computed tomography (CT) and high resolution CT for the early diagnosis of lung and pleural disease in workers exposed to asbestos: Finnish experiences. In: Proceedings of an international expert meeting on new advances in radiology and screening of asbestos-related diseases. Helsinki, Finnish Inst. of Occupational Health, People and Work Research Reports 36 (2000), 53-56.
91. T. Vierikko, R. Järvenpää, T. Autti, P. Oksa, M. Huuskonen, S. Kaleva, J. Laurikka, S. Kajander, K. Paakkola, S. Saarelainen, E.-R. Salomaa, A. Tossavainen, P. Tukiainen, J. Uitti and T. Vehmas, Chest CT screening of asbestos-exposed workers: lung lesions and incidental findings, Eur respire J 29 (2007), 78-84.
92. G.-P. Wu, E.-H. Wang, J.-H. Li, Z.-M. Fu and S. Han, Clinical application of the liquid-based cytological test in cytological screening of sputum for the diagnosis of lung cancer, Respirology 14 (2009), 124-128.
93. K. Yamaguchi and P. Stieber, Diagnosis of Small Cell Lung Cancer by Pro Gastrin Releasing Peptide (ProGRP), J Lab Med 27 (2003), 26-30.
94. H. B. Yang, P. I. Hsu, J. C. Lee, C. H. Chan, X. Z. Lin and N. H. Chow, Adenoma-carcinoma sequence: areappraisal with immuno-histochemical expression of ferritin, J Surg Oncol 60 (1995), 35-40.
95. L. A. Zadeh, Fuzzy sets, Information and Control 8 (1965), 35-40.
96. H. J. Zimmermann, Fuzzy Set Theory and its Application, (2nd edn.), Kluwer, 1991, Boston.
97. G. Mastrangelo, M. N. Ballarin, E. Bellini, R. Bizzotto, F. Zannol, F. Gioffre, M. Gobbi, G. Tessadri, L. Marchiori, G. Marangi, S. Bozzolan, JH. Lange, F. Valentini and P. Spolaore, Feasibility of a screening programme for lungcancer in former asbestos workers, Occup Med 58 (2008), 175-180.